Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-17-8463-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.22 billion
Profitability
Miscellaneous
Employees3,700
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) issued its quarterly earnings data on Tuesday, August, 6th. The company reported $2.53 EPS for the quarter, beating the consensus estimate of $2.10 by $0.43. The firm earned $823.30 million during the quarter, compared to analyst estimates of $817.55 million. Mallinckrodt had a positive return on equity of 18.96% and a negative net margin of 111.46%. The business's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.16 EPS. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What guidance has Mallinckrodt issued on next quarter's earnings?
Mallinckrodt issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of $8.40-8.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.22.
What price target have analysts set for MNK?
15 Wall Street analysts have issued 12-month price targets for Mallinckrodt's shares. Their forecasts range from $2.00 to $22.00. On average, they expect Mallinckrodt's stock price to reach $9.4667 in the next year. This suggests a possible upside of 214.5% from the stock's current price. View Analyst Price Targets for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 11 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.
What are Wall Street analysts saying about Mallinckrodt stock?
Here are some recent quotes from research analysts about Mallinckrodt stock:
- 1. According to Zacks Investment Research, "Mallinckrodt’s hospital franchise (Inomax and Ofirmev) has gained traction which is positively impacting performance. The spin-off of the generic business appears to be a step in the right direction as this will enable Mallinckrodt to focus better on the branded business, which promises potential. Mallinckrodt has streamlined its business of late to focus better on its innovative medicines and therapies. The company has been involved in quite a few lawsuits for its alleged role in the current opioid epidemic in the United States through its marketing and promotion practices. Shares have outperformed the industry in the last six months. However, pipeline setbacks continue to weigh on the company. The CRL for stannsoporfin was disappointing. Acthar, Mallinckrodt’s largest product, is being impacted by the residual impact of the previously reported patient withdrawal issues." (1/8/2019)
- 2. Mizuho analysts commented, "We reiterate our Neutral rating into what we view as risky read-outs for VTS-270 in Niemann- Pick Type C, and CPP-1X/Sulindac in FAP." (11/6/2018)
Has Mallinckrodt been receiving favorable news coverage?
News headlines about MNK stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mallinckrodt earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Mallinckrodt.
Are investors shorting Mallinckrodt?
Mallinckrodt saw a increase in short interest in August. As of August 31st, there was short interest totalling 42,719,500 shares, an increase of 10.1% from the July 31st total of 38,783,500 shares. Based on an average trading volume of 3,680,000 shares, the days-to-cover ratio is presently 11.6 days. Approximately 51.8% of the company's stock are short sold. View Mallinckrodt's Current Options Chain.
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Esperion Therapeutics (ESPR), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), Endo International (ENDP), ArQule (ARQL), Cara Therapeutics (CARA), Omeros (OMER), Odonate Therapeutics (ODT), ANI Pharmaceuticals (ANIP), Stoke Therapeutics (STOK), Homology Medicines (FIXX), Phibro Animal Health (PAHC), Arvinas (ARVN), NextCure (NXTC) and Wave Life Sciences (WVE).
What other stocks do shareholders of Mallinckrodt own?
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
- Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
- Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.82%), Vanguard Group Inc. (11.68%), LSV Asset Management (4.65%), Morgan Stanley (3.90%), AQR Capital Management LLC (3.00%) and Invesco Ltd. (2.43%). Company insiders that own Mallinckrodt stock include Bryan M Reasons, David R Carlucci, Dr Kneeland Youngblood, James E Flynn, Joann A Reed, Mark Trudeau, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.
Which major investors are selling Mallinckrodt stock?
MNK stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Coatue Management LLC, Bank of New York Mellon Corp, Schroder Investment Management Group, Schroder Investment Management Group, Prudential Financial Inc., Panagora Asset Management Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Mallinckrodt.
Which major investors are buying Mallinckrodt stock?
MNK stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Vanguard Group Inc., Connor Clark & Lunn Investment Management Ltd., Invesco Ltd., Maverick Capital Ltd., Nuveen Asset Management LLC, Luminus Management LLC and State of New Jersey Common Pension Fund D. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons, David R Carlucci, Dr Kneeland Youngblood, Joann A Reed, Mark Trudeau, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $3.01.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $252.87 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe.View Additional Information About Mallinckrodt.
What is Mallinckrodt's official website?
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
